CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy.
Silbert SK, Scanlon S, Wang HW, Yuan CM, Doverte A, Wellek J, Patel N, Braylan R, Ahlman M, Turkbey EB, Bohling SD, Chisholm KM, Oztek MA, LaLoggia M, Verma A, Shalabi H, Kovach AE, Wood BL, Lamble A, Kirsch I, Leger K, Shah NN.
Silbert SK, et al. Among authors: wang hw.
J Immunother Cancer. 2024 Oct 26;12(10):e009499. doi: 10.1136/jitc-2024-009499.
J Immunother Cancer. 2024.
PMID: 39461880
Free article.